Patent Expirations and Market Impact
Aclidinium bromide (Tudorza Pressair)
Mechanism of Action: Muscarinic M3 receptor antagonists Drug class: Small molecules Originator: Almirall-Prodesfarma Developer: Allergan; Almirall S.A.; AstraZeneca; Covis Pharma; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical Indications: Chronic obstructive pulmonary disease (COPD) Patent expiry: February 2025
Tudorza Pressair market revenue for twelve years (2013-Q12024)
The global market for Aclidinium Bromide is set for steady growth, driven by the rising prevalence of chronic obstructive pulmonary disease (COPD). In January 2022, Covis Pharma acquired the global rights to Tudorza Pressair from AstraZeneca. Tudorza Pressair’s revenue has fluctuated significantly over the past eleven years. As part of the deal, AstraZeneca sold the global rights for Eklira (Tudorza in the U.S.) and Duaklir to Covis Pharma for an upfront payment of $270 million, recorded under Other Operating Income and Expense. The intangible assets of $368 million were classified as Assets held for sale as of December 31, 2021. Revenue declined in 2019 due to increased competition from other COPD drugs.
“AstraZeneca transferred global rights for Eklira (Tudorza in the U.S.) and Duaklir to Covis Pharma for a $270 million upfront payment, recorded as Other Operating Income and Expense.”
How will the patent expiry of Tudorza Pressair affect the market?
The patent expiration of Tudorza Pressair is expected to have a major impact on Covis Pharma’s revenue, likely resulting in a significant sales decline as generic versions enter the market. This will increase price competition and reduce market share for the branded product, potentially affecting the company’s overall financial performance.
“As the patent for Tudorza Pressair expire, generic versions will enter the market, increasing competition and likely reducing sales for AstraZeneca’s branded products.”